PP
CBMG

Paloma Partners’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Paloma Partners’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,740
Closed -$362K – 2458
2020
Q3 		$362K Buy
+19,740
New +$332K 0.01% 1361
2017
Q3 		– Sell
-44,525
Closed -$390K – 2590
2017
Q2 		$390K Buy
+44,525
New +$392K ﹤0.01% 1681

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paloma Partners's CBMG Position: Q4 2020 in Review

Paloma Partners sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2020, closing a stake of 19,740 shares — an estimated $362K sold.

Paloma Partners first reported a position in CBMG in Q2 2017 and held it in 2 quarters. The position peaked at $390K in Q2 2017. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

  • Paloma Partners reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2020 after selling out during the quarter.
  • Paloma Partners sold 19,740 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $362K.
  • Paloma Partners first reported a position in Cellular Biomedicine Group, Inc. in Q2 2017 and held it in 2 quarters.
  • Paloma Partners's Cellular Biomedicine Group, Inc. position peaked at $390K in Q2 2017.
  • 67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.